Shots:
- Merz Therapeutics has enrolled the first patients in two global P-III studies, MINT-E (episodic migraine, ~990 pts) and MINT-C (chronic migraine, ~780 pts), evaluating the efficacy and safety of Xeomin (incobotulinumtoxinA) for migraine prevention
- Both studies will recruit ~1,770 adults across 120 sites in North America & Europe, and recruitment in Europe is expected shortly; the primary endpoint is a reduction in monthly migraine days at 6mos., with secondary endpoints covering headache days, acute medication use, and migraine frequency during two-week periods at the end of each injection cycle
- Xeomin (incobotulinumtoxinA) is a prescription medicine injected into muscles or glands to treat chronic drooling (sialorrhea) in adults and children, eyelid spasm (blepharospasm) and hemifacial spasm in adults, twisted neck (spasmodic torticollis), and upper limb spasticity
Ref: Merz Therapeutics | Image: Merz Therapeutics | Press Release
Related News:- PDS Biotech Reports Final P-II (VERSATILE-002) Survival Data for PDS0101 + Keytruda in 1L HPV16+ Head & Neck Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
